Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail

Journal of Hepatology

Volumn 53, Issue 1, 2010, Pages 23-24

  Trinchet, Jean Claude ^a   Beaugrand, Michel ^a  

^a HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; PROTHROMBIN; SERUM ALBUMIN; SORAFENIB;

ASCITES; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER SURVIVAL; CHEMOEMBOLIZATION; EDITORIAL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; BIOLOGICAL MODEL; CLASSIFICATION; HUMAN; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PROGNOSIS;

EID: 77953569035     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.04.002     Document Type: Editorial

References (22)

1. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
2. Minagawa M., Ikai I., Matsuyama Y., Yamaoka Y., and Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 245 (2007) 909-922
3. Pascual S., Zapater P., Such J., Garcia-Herola A., Sempere L., Irurzun J., et al. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 26 (2006) 673-679
4. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
5. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma. The BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
6. Chevret S., Trinchet J.C., Mathieu D., Rached A.A., Beaugrand M., and Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 31 (1999) 133-141
7. Perrone F., Daniele B., Gaeta G.B., Pignata S., Gallo C., Izzo F., et al. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31 (2000) 840-845
8. Leung T., Tang A., Zee B., Lau W., Lai P., Leung K., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94 (2002) 1760-1769
9. Kudo M., Chung H., Haji S., Osaki Y., Oka H., Seki T., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
10. Hsu C.Y., Huang Y.H., Hsia C.Y., Su C.W., Lin H.C., Loong C.C., et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume. The Taipei Integrated Scoring system. J Hepatol 53 (2010) 108-117
11. Marrero J.A. Staging systems for hepatocellular carcinoma: should we all use the BCLC system?. J Hepatol 44 (2006) 630-632
12. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41 (2005) 707-716
13. Cillo U., Bassanello M., Vitale A., Grigoletto F., Burra P., Fagiuoli S., et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol 40 (2004) 124-131
14. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25 (2005) 143-154
15. Leykum L.K., El-Serag H.B., Cornell J., and Papadopoulos K.P. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 5 (2007) 508-512
16. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
17. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
18. Yau T., Yao T.J., Chan P., Ng K., Fan S.T., and Poon R.T. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 113 (2008) 2742-2751
19. Grieco A., Pompili M., Caminiti G., Miele L., Covino M., Alfei B., et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54 (2005) 411-418
20. Tateishi R., Yoshida H., Shiina S., Imamura H., Hasegawa K., Teratani T., et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54 (2005) 419-425
21. Toyoda H., Kumada T., Osaki Y., Oka H., Urano F., Kudo M., et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 4 (2006) 1528-1536
22. Kong S.Y., Park J.W., Lee J.A., Park J.E., Park K.W., Hong E.K., et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46 (2007) 446-455